Drugs / SHR-9803
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06906731 | Apr 2025 → Jun 2027 expected | cancer | Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SHR-9803 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06906731 ↗ |